Patients with multiple myeloma and dialysis-dependent renal failure have dismal outcomes. In this retrospective analysis of a case series, we evaluated 27 consecutive patients, all of whom required haemodialysis at the time of first-line induction therapy with either bortezomib or a standard regimen followed by high-dose chemotherapy and auto-SCT. The overall response rate was significantly better after bortezomib-based induction before auto-SCT (83% vs 36%, P = 0.02) and at day +100 post auto-SCT (100% vs 58%, P = 0.01). Bortezomib also prolonged EFS and furthermore, a trend towards a shorter time on haemodialysis was observed in the bortezomib group at a median of 6.1 months (0.2-68.2 months) vs 17.1 months (0.7-94.3 months, P = 0.38) in patients who had received vincristine, adriamycin, dexamethasone or vincristine, adriamycin, dexamethasone-like induction regimens. These data demonstrate the superior efficacy of bortezomib-based induction therapy in transplant-eligible patients with end-stage renal failure.
INTRODUCTION
Approximately 30% of patients with newly diagnosed multiple myeloma (MM) present with renal insufficiency (RI). [1] [2] [3] [4] Before starting treatment, between 1 and 13% of patients require haemodialysis and this cohort has been reported to have a particularly poor outcome. [2] [3] [4] [5] [6] MM patients with dialysisdependent RI are not usually considered eligible for myeloablative chemotherapy owing to a higher risk of treatment-related toxicity. We and others, however, have previously reported that patients with end-stage renal failure requiring haemodialysis who undergo high-dose chemotherapy and auto-SCT had rates of posttransplant toxicity, as well as EFS and OS, that were comparable to those of patients with normal kidney function. 7, 8 This suggests that high-dose therapy is able to overcome the adverse prognostic significance of dialysis-dependent RI.
Bortezomib has been reported to be safe and efficacious in patients with renal impairment. [9] [10] [11] [12] There are, however, no comparative data relating to patients with newly diagnosed dialysis-dependent MM. The aim of this retrospective analysis was to compare the efficacy of bortezomib-based induction regimens against that of vincristine, doxorubicin and dexamethasone (VAD)-like regimens in patients with dialysis-dependent RI before auto-SCT.
MATERIALS AND METHODS
In this retrospective case analysis, we evaluated outcome data on 27 consecutive patients with newly diagnosed MM requiring undefined who went on to receive first-line induction therapy followed by stem cell mobilization, high-dose chemotherapy and auto-SCT at our centre between 1997 and 2011. Patient eligibility criteria included newly diagnosed MM, dialysis dependency due to MM-related renal failure and induction treatment with either PAD (bortezomib, doxorubicin, dexamethasone) or VAD/VAD-like regimens. VAD remained the standard induction regimen for patients with end-stage renal failure until bortezomib became available for first-line therapy. Data assessment was approved by the institutional review board (ethics committee of the Heidelberg University Hospital, Germany) and written informed consent was obtained from all patients for treatment and data analysis. Response criteria were defined according to the EBMT guidelines. 13 To compare quantitative data, Wilcoxon signed rank test and Fisher's exact test were used for nominal parameters. Survival and time-to-event data analyses were analysed using Cox's proportional harzards model.
RESULTS AND DISCUSSION
Renal failure in newly diagnosed myeloma patients has been reported to be of adverse prognostic significance. [2] [3] [4] [5] [6] According to the results of the ERA-EDTA registry study, the incidence of renal replacement therapy due to MM has increased over the past 20 years in Europe with a median survival of 0.91 years.
14 Over recent years, however, studies on the safety and efficacy of newer treatment regimens including auto-SCT have confirmed the tolerability of these approaches in this patient group and corresponding improvements in response rates and OS.
Patient characteristics In our analysis of 27 patients, the isotypic breakdown was as follows: 12 patients had light chain disease, 10 IgG, 3 IgA, 1 IgD and 1 oligosecretory MM (Table 1 ). A total of 13 patients received a bortezomib-containing regimen, PAD (bortezomib, adriamycin and dexamethasone; n = 12) or VCD (bortezomib, cyclophosphamide and dexamethasone; n = 1) and the outcome of this group was compared with that of 14 patients who received VAD (n = 11) or a VAD-like induction regimen (thalidomide, adriamycin and dexamethasone, TAD, n = 1). One patient received TCED (thalidomide, cyclophosphamide, etoposide and dexamethasone) ( Table 1) . One patient in the PAD group had been given VAD in the first cycle of induction but was then switched to a bortezomibcontaining regimen. All but two of these patients were dialysis dependent from the start of treatment, whereas two patients started haemodialysis shortly after starting the treatment; hence, the maximum creatinine clearance value of 49 mL/min at the time of diagnosis (bortezomib group) and β 2 -microglobulin of 4.8 mg/L (control group).
All patients received cyclophosphamide, doxorubicin and dexamethasone (CAD) followed by G-CSF for stem cell mobilization. For high-dose chemotherapy, melphalan was administered in all of the 27 patients. Patients who came off dialysis before auto-SCT received full dose of melphalan (100 mg/m 2 day − 3 and − 2), whereas patients still dependent on dialysis were conditioned with one dose of melphalan (100 mg/m 2 , day − 2) after dialysis on that day, followed by dialysis the day after high-dose therapy (day − 1). Notably, no difference was seen in post-transplant toxicity, as assessed by time to recovery of leucocytes (41/nL), granulocytes (40.5/nL) and thrombocytes (420, 450/nL), days of hospitalization or supportive treatment (Table 2) between the standard and bortezomib group. A total of 17 patients went on to receive maintenance therapy post auto-SCT. For those patients who did not receive bortezomib before auto-SCT, maintenance treatment consisted of alpha-IFN in three patients. Thalidomide was given to two patients of the bortezomib group and to eight patients of the VAD/VAD-like group. A total of four patients who received a bortezomib-containing induction regimen was also given bortezomib as maintenance. Overall, patient characteristics were comparable between the two groups, as presented in Table 1 . From 6 patients of the standard and 10 patients of the bortezomib group, cytogenetic data were available (Table 3 ) and comparable in both groups.
Renal recovery Data on renal function, as assessed by the creatinine clearance, were available at baseline and before transplant in all cases. The median duration of dialysis dependency after the start of treatment as a marker for recovery of renal function was 6.1 months (0.2-68.2 months) in the bortezomib group vs 17.1 months (0.7-94.3 months) in patients who had received Abbreviations: CAD = cyclophosphamide, doxorubicin and dexamethasone; CreaCl = creatinine clearance; Est. = estimated; MG = microglobulin; NA = not available; NS = not significant; ORR = overall response rate; PAD = bortezomib, adriamycin and dexamethasone; VAD = vincristine, doxorubicin and dexamethasone; VCD = bortezomib, cyclophosphamide and dexamethasone; TAD = thalidomide, adriamycin and dexamethasone; TCED = thalidomide, cyclophosphamide, etoposide and dexamethasone. Our results are in line with the findings of Parikh et al. who reported that high-dose therapy and auto-SCT may reverse renal failure in MM patients. In their study, 46 patients with RI and 10 on haemodialysis underwent high-dose therapy with melphalan at standard doses. No increase in treatment-related toxicity or nonrelapse mortality was seen. However, a significant improvement in renal function, defined as an increase in the glomerular filtration rate by 425% above baseline, was observed in 32% of patients. 15 Similarly, Badros et al. investigated 81 MM patients with RI, of whom 38 had been dialysis dependent at the time of auto-SCT. Twenty-seven dialysis-dependent patients had received melphalan 200 mg/m 2 and due to toxicity, another 21 dialysis-dependent patients had been given melphalan 140 mg/m 2 . A total of 11 dialysis-dependent patients underwent tandem auto-SCT. They found that RI did not affect engraftment and melphalan 140 mg/m 2 resulted in tolerable non-haematological toxicity. Treatment related mortality (TRM) was 6% after single and 13% after tandem auto-SCT. Overall, two patients came off dialysis. 8 Controversially, Glavey and colleagues analysed the association of the renal outcome from myeloma patients with renal impairment who underwent auto-SCT. In this retrospective analysis, after auto-SCT improvement of glomerular filtration rate was noted; however, 14 out of 15 patients remained dialysis dependent despite haematological response. So they concluded that auto-SCT was not associated with independence from dialysis. 16 Furthermore, in a retrospective analysis of 117 MM patients with RI of whom 14 required dialysis, reversal of RI was observed in 41% of patients after bortezomib-based therapy. Moreover, three of these patients were able to come off haemodialysis. Another study reported on the reversal of acute light-chain deposition disease-associated renal failure in five out of eight patients following bortezomib-based treatment, and the authors noted that the improvement in renal function was preceded by a significant reduction in paraprotein concentration. 11 Chanan-Khan et al. reported on the safety and efficacy of bortezomib in 23 patients requiring dialyses. Here, three patients became independent of dialysis, one was spared dialysis. The authors concluded that bortezomib can safely be used in MM requiring haemodialysis with manageable toxicity. 9 Response rates and survival The overall response rate (PR or better) was significantly higher after bortezomib-based induction before auto-SCT (83.3% vs 35.7%, P = 0.021). The subsequent administration of myeloablative chemotherapy further improved the depth of response in both groups. Importantly, the significant advantage conferred by bortezomib was retained at day +100 post auto-SCT (100% vs 58.3%, P = 0.014). Similar results have been reported in the nontransplant setting of relapsed disease. A multi-centre retrospective study evaluated the activity and safety of bortezomib in 24 MM patients with advanced renal failure, 23 requiring haemodialysis. The majority of patients had received at least two prior therapies. Patients had received bortezomib alone or in combination. The overall response rate was 75%, with 30% CR and near CR. 9 With respect to the VAD group, our results are comparable to the findings of Badros et al., 8 who found a CR rate of 26% after first and of 38% after second auto-SCT in patients with RI and further showed that neither EFS nor OS were affected by RI or melphalan dose.
In a matched pair analysis, we recently demonstrated that, when patients with dialysis-dependent RI undergoing high-dose therapy and auto-SCT were compared with those with normal renal function, there was no significant difference in the rates of haematologic toxicity, TRM or disease response. Moreover, patients on dialysis had comparable EFS and OS. 7 In our current analysis, which is restricted to patients with end-stage renal failure, there is a longer EFS in favour of the bortezomib group. The estimated median EFS has not yet been reached in the bortezomib group as compared with 28 months in the VAD or VAD-like group (hazard ratio 0.39, confidence interval 0.14-0.98, P = 0.04), after an estimated median follow-up time of 53 months (bortezomib) and 84 months (VAD) from the start of therapy, respectively (Figure 1) . Similarly, the median OS has not been reached after bortezomib induction therapy compared with 35 months for the control group (hazard ratio 0.51, confidence interval 0.18-1.46, P = 0.21) (Figure 2 ). Although the survival difference is not statistically significant, these data underline the promising efficacy of bortezomib for patients with end-stage renal failure when administered as first-line induction therapy followed by high-dose therapy and auto-SCT. We further assessed, whether maintenance treatment had an impact on EFS and OS. We compared the data of the 10 patients who did not receive maintenance treatment with those who either received thalidomide (n = 10), IFN (n = 3) or bortezomib (n = 4) and found a significantly longer EFS (median, 29.9 vs 47 months, P = 0.006) in favour of patients on maintenance therapy, whereas OS was not found to be significantly different (median, 28.7 vs 37 months, P = 0.16). Owing to small patient numbers, no subgroup analysis was applied.
Novel agents and techniques With the availability of novel agents, the treatment options for patients with RI have widened. In a recent review, Dimopoulos et al. 17 concluded that, for patients with newly diagnosed myeloma and concomitant renal impairment, bortezomib-based induction is associated with the best renal outcomes when compared with those reported for regimens based on immunomodulatory agents.
The urgent need for clinical trials of novel therapeutic strategies to restore or preserve dialysis-independent renal function and to improve the outcome for this group of patients was emphasized in a retrospective analysis of 107 patients with RI by Haynes et al. 18 The potential role of novel haemodialysis techniques in removing light chains and thereby improving renal function was specifically highlighted. 18, 19 Several haemodialysis techniques have recently become available for patients with dialysis-dependent acute renal failure secondary to myeloma kidney; extended high cut-off haemodialysis in combination with standard chemotherapy seems to improve renal function. 20 Besides chemotherapy, extracorporeal elimination procedures such as plasma exchange have been applied as adjuvant strategies to eliminate free light chains from circulating blood. Leung et al. 21 found that plasma exchange to remove light chains was associated with renal recovery in patients with cast nephropathy. Whether the application of novel renal replacement techniques in combination with bortezomib-containing induction therapy in the transplant setting will further improve kidney function in MM patients with RI is currently being investigated in clinical trials.
In conclusion, bortezomib is safe and effective when used in the setting of first-line induction therapy before auto-SCT in patients with end-stage renal failure and should be considered the standard of care in this patient population.
